<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676048</url>
  </required_header>
  <id_info>
    <org_study_id>ASC-HA-001</org_study_id>
    <nct_id>NCT04676048</nct_id>
  </id_info>
  <brief_title>ASC618 Gene Therapy in Hemophilia A Patients</brief_title>
  <official_title>Assessment of Safety and Preliminary Efficacy of ASC618 in Subjects With Severe and Moderately Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ASC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ASC Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, hemophilia A patients are managed with prophylactic or on-demand replacement&#xD;
      therapy with recombinant FVIII or alternative therapeutics. The major challenges of current&#xD;
      treatment regimens, such as the short half-life of hemophilia therapeutics with the need for&#xD;
      frequent IV injections, encourage the current efforts for gene transfer therapy.&#xD;
&#xD;
      This study will evaluate the safety and preliminary efficacy of ASC618, an AAV vector&#xD;
      encoding B-domain deleted codon-optimized human factor VIII under a synthetic liver-directed&#xD;
      promoter&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2022</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events, and serious AEs</measure>
    <time_frame>12 months post-infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in FVIII activity levels from baseline</measure>
    <time_frame>12 months post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized FVIII consumption</measure>
    <time_frame>12 months post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized bleeding rate (ABR)</measure>
    <time_frame>12 months post-infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>ASC618</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ASC618</intervention_name>
    <description>ASC618 will be given as a single IV infusion</description>
    <arm_group_label>ASC618</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male ≥18 years of age&#xD;
&#xD;
          -  Severe or moderately severe hemophilia A (FVIII activity ≤ 2 IU/dL) as evidenced by&#xD;
&#xD;
          -  medical history&#xD;
&#xD;
          -  Received FVIII prophylactic or on-demand replacement therapy for ≥ 150 accumulated&#xD;
&#xD;
          -  days (exposure days)&#xD;
&#xD;
          -  ≥12 bleeding episodes if receiving on-demand therapy over the preceding 12 months&#xD;
&#xD;
          -  BMI ≤ 30&#xD;
&#xD;
          -  Agree to use double-barrier contraceptive until at least 3 consecutive semen samples&#xD;
             are negative after ASC-618 infusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing immunity to AAV8 vector as defined by AAV8 total antibodies and&#xD;
             neutralizing antibodies qualified tests.&#xD;
&#xD;
          -  Current inhibitors, or history of high titer FVIII inhibitors&#xD;
&#xD;
          -  Presence of &gt; Grade 2 liver fibrosis on elastography/Fibroscan or comparable imaging&#xD;
             methodology&#xD;
&#xD;
          -  History of chronic renal disease&#xD;
&#xD;
          -  Active infection or any immunosuppressive disorder&#xD;
&#xD;
          -  History of cardiac surgery and need anticoagulant therapy&#xD;
&#xD;
          -  Any cardiovascular / genetic risk factors for thromboembolic disorders&#xD;
&#xD;
          -  Evidence of active Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV)-1/2 or&#xD;
             syphilis infection.&#xD;
&#xD;
          -  Receipt of any vector or gene transfer agent&#xD;
&#xD;
          -  Current antiviral therapy for hepatitis B or C&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trial Manager, PhD</last_name>
    <phone>(408) 495-3891</phone>
    <email>gil.gonen@asctherapeutics.com</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

